[{"orgOrder":0,"company":"ValiRx","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"UNITED KINGDOM","productType":"Peptide","year":"2020","type":"Agreement","leadProduct":"VAL301","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"ValiRx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ValiRx \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"ValiRx \/ Undisclosed"},{"orgOrder":0,"company":"Vectura Ltd","sponsor":"Monash University","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"UNITED KINGDOM","productType":"Hormone","year":"2020","type":"Agreement","leadProduct":"Oxytocin","moa":"CGRP receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Vectura Ltd","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Vectura Ltd \/ Monash University","highestDevelopmentStatusID":"4","companyTruncated":"Vectura Ltd \/ Monash University"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Details : Vectura will support the development of a single use device/formulation combination for evaluation in Phase I of inhaled oxytocin, and then expedite technical transfer to a commercial manufacturer to advance to Phase III and commercial launch.

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Undisclosed

                          September 14, 2020

                          Lead Product(s) : Oxytocin

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Preclinical

                          Sponsor : Monash University

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          Skyepharma Company Banner

                          02

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Agreement signed with the company will see VAL301 evaluated for the purpose of contemplating a potential future license for the treatment of endometriosis.

                          Product Name : VAL301

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          January 05, 2020

                          Lead Product(s) : VAL301

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Preclinical

                          Sponsor : Undisclosed

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank